Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis

Journal of Dermatology

Volumn 37, Issue 1, 2010, Pages 42-53

  Hamaguchi, Yasuhito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Antinuclear antibodies; Clinical features; Prognosis; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; CENTROMERE ANTIBODY; DNA TOPOISOMERASE; KU ANTIGEN; RNA POLYMERASE;

ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; CELLULAR DISTRIBUTION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HUMAN; IMMUNODIFFUSION; IMMUNOPRECIPITATION; LUNG FIBROSIS; MORTALITY; PREDICTIVE VALIDITY; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC SCLEROSIS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CELL NUCLEOLUS; DNA TOPOISOMERASES, TYPE I; DNA-DIRECTED RNA POLYMERASES; HUMANS; HYPERTENSION, PULMONARY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 75649110071     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00762.x     Document Type: Review

References (104)

1. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988 15: 202 205.
2. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989 44: 93.
3. Fanning GC, Welsh KI, Bunn C, Du Bois R, Black CM. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998 37: 201 207.
4. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996 22: 709 735.
5. Lischwe MA, Ochs RL, Reddy R et al. Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34,000; pI, 8.5) rich in NG,NG-dimethylarginine. J Biol Chem 1985 260: 14304 14310.
6. Harvey G, Black C, Maddison P, McHugh N. Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 1997 24: 477 484.
7. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003 5: 80 93.
8. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003 49: 399 412.
9. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005 35: 35 42.
10. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994 37: 75 83.
11. Hamaguchi Y, Hasegawa M, Fujimoto M et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008 158: 487 495.
12. Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 1980 77: 1627 1631.
13. Earnshaw WC, Machlin PS, Bordwell BJ, Rothfield NF, Cleveland DW. Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B. Proc Natl Acad Sci USA 1987 84: 4979 4983.
14. Masumoto H, Masukata H, Muro Y, Nozaki N, Okazaki T. A human centromere antigen (CENP-B) interacts with a short specific sequence in alphoid DNA, a human centromeric satellite. J Cell Biol 1989 109: 1963 1973.
15. Rothfield N, Whitaker D, Bordwell B, Weiner E, Senecal JL, Earnshaw W. Detection of anticentromere antibodies using cloned autoantigen CENP-B. Arthritis Rheum 1987 30: 1416 1419. (Pubitemid 18051914)
16. Tan EM, Smolen JS, McDougal JS et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999 42: 455 464.
17. McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989 32: 54 60.
18. Reveille JD, Fischbach M, McNearney T et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001 30: 332 346.
19. Makinen D, Fritzler M, Davis P, Sherlock S. Anticentromere antibodies in primary biliary cirrhosis. Arthritis Rheum 1983 26: 914 917.
20. Lee SL, Tsay GJ, Tsai RT. Anticentromere antibodies in subjects with no apparent connective tissue disease. Ann Rheum Dis 1993 52: 586 589.
21. Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988 47: 634 641.
22. McHugh NJ, Whyte J, Artlett C et al. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin Exp Immunol 1994 96: 267 274. (Pubitemid 24213833)
23. Genth E, Mierau R, Genetzky P et al. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 1990 33: 657.
24. Sato H, Lagan AL, Alexopoulou C et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 2004 50: 558 564.
25. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980 23: 617 625.
26. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. A comparison between anti-Th/To-and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003 48: 203 209.
27. Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002 81: 139 153.
28. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003 42: 534 540.
29. Tramposch HD, Smith CD, Senecal JL, Rothfield N. A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984 27: 121 124.
30. Vazquez-Abad D, Russell CA, Cusick SM, Earnshaw WC, Rothfield NF. Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol Immunopathol 1995 74: 257 270.
31. Scussel-Lonzetti L, Joyal F, Raynauld JP et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002 81: 154 167.
32. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979 254: 10514 10522.
33. Shero JH, Bordwell B, Rothfield NF, Earnshaw WC. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986 231: 737 740.
34. Reveille JD, Durban E, MacLeod-St Clair MJ et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992 90: 973 980.
35. Kuwana M, Kaburaki J, Okano Y, Inoko H, Tsuji K. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest 1993 92: 1296 1301.
36. Dick T, Mierau R, Bartz-Bazzanella P et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 2002 61: 121 127.
37. Ruffatti A, Calligaro A, Ferri C, Bombardieri S, Gambari PF, Todesco S. Association of anti-centromere and anti-Scl 70 antibodies in scleroderma. Report of two cases. J Clin Lab Immunol 1985 16: 227 229.
38. Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med 1997 103: 242 248.
39. Walker UA, Tyndall A, Czirjak L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007 66: 754 763.
40. Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol 1979 115: 950 955.
41. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985 12: 1136 1139.
42. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988 31: 378 385.
43. Rothfield N, Kurtzman S, Vazques-Abad D, Charron C, Daniels L, Greenberg B. Association of anti-topoisomerase I with cancer. Arthritis Rheum 1992 35: 724.
44. Derk CT, Sakkas LI, Rasheed M, Artlett C, Jimenez SA. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol 2003 30: 1994 1996.
45. Henry PA, Atamas SP, Yurovsky VV, Luzina I, Wigley FM, White B. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. Arthritis Rheum 2000 43: 2733 2742.
46. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000 43: 1074 1084.
47. Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemimc sclerosis. Rheumatology 2001 40: 1135 1140.
48. Hamaguchi Y, Fujimoto M, Hasegawa M, Matsushita T, Takehara K. Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis. J Am Acad Dermatol 2009.
49. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000 133: 600 603.
50. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006 54: 963 973.
51. Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Antoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993 91: 1399 1404.
52. Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993 119: 1005 1013.
53. Satoh M, Ajmani AK, Ogasawara T et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 1994 94: 1981 1989.
54. Falkner D, Wilson J, Fertig N, Clawson K, Medsger TA Jr., Morel PA. Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol 2000 27: 1196 1202.
55. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004 16: 723 732.
56. Reimer G, Steen VD, Penning CA, Medsger TA Jr., Tan EM. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988 31: 525 532.
57. Okano Y, Medsger TA Jr. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990 33: 1822 1828.
58. Yamane K, Ihn H, Kubo M et al. Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma. Rheumatology (Oxford) 2001 40: 683 686.
59. Hashimoto C, Steitz JA. Sequential association of nucleolar 7-2 RNA with two different autoantigens. J Biol Chem 1983 258: 1379 1382.
60. Reddy R, Tan EM, Henning D, Nohga K, Busch H. Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 1983 258: 1383 1386.
61. Falkner D, Wilson J, Medsger TA Jr., Morel PA. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum 1998 41: 74 80.
62. Van Eenennaam H, Vogelzangs JH, Bisschops L et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002 130: 532 540.
63. Gunduz OH, Fertig N, Lucas M, Medsger TA Jr. Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. Arthritis Rheum 2001 44: 1663 1666.
64. Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001 40: 1157 1162.
65. Arnett FC, Reveille JD, Goldstein R et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996 39: 1151 1160.
66. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009 60: 1112 1118.
67. Rodriguez-Sanchez JL, Gelpi C, Juarez C, Hardin JA. Anti-NOR 90. A new autoantibody in scleroderma that recognizes a 90-kDa component of the nucleolus-organizing region of chromatin. J Immunol 1987 139: 2579 2584.
68. Chan EK, Imai H, Hamel JC, Tan EM. Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor. J Exp Med 1991 174: 1239 1244.
69. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992 140: 859 870.
70. Dagher JH, Scheer U, Voit R et al. Autoantibodies to NOR 90/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol 2002 29: 1543 1547.
71. Fujii T, Mimori T, Akizuki M. Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 1996 39: 1313 1318.
72. Dick T, Mierau R, Sternfeld R, Weiner EM, Genth E. Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90). J Rheumatol 1995 22: 67 72.
73. Wassarman KM, Steitz JA. The low-abundance U11 and U12 small nuclear ribonucleoproteins (snRNPs) interact to form a two-snRNP complex. Mol Cell Biol 1992 12: 1276 1285.
74. Fertig N, Domsic RT, Rodriguez-Reyna T et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009 61: 958 965.
75. Jacobsen S, Halberg P, Ullman S et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998 37: 39 45.
76. Lundberg I, Hedfors E. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 1991 18: 1511 1519.
77. Ricken D. Progressive scleroderma and dermatomyositis. Verh Dtsch Ges Inn Med 1977 83: 751 756.
78. Brouwer R, Vree Egberts WT, Hengstman GJ et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002 4: 134 138.
79. Reichlin M, Maddison PJ, Targoff I et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984 4: 40 44.
80. Marguerie C, Bunn CC, Copier J et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992 71: 327 336.
81. Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 1981 68: 611 620.
82. Takeda Y, Dynan WS. Autoantibodies against DNA double-strand break repair proteins. Front Biosci 2001 6: D1412 D1422.
83. Franceschini F, Cavazzana I, Generali D et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol 2002 29: 1393 1397.
84. Rozman B, Cucnik S, Sodin-Semrl S et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 2008 67: 1282 1286.
85. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986 146: 2153 2156.
86. Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G. Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Autoimmunity 1995 20: 1 7.
87. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002 46: 1019 1027. (Pubitemid 34303815)
88. Pope JE, Thompson A. The frequency and significance of anticardiolipin antibodies in scleroderma. J Rheumatol 2000 27: 1450 1452.
89. Malia RG, Greaves M, Rowlands LM et al. Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Clin Exp Immunol 1988 73: 456 460.
90. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996 101: 576 583.
91. Ihn H, Sato S, Fujimoto M et al. Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis. Clin Exp Immunol 1996 105: 475 479.
92. Hasegawa M, Sato S, Yanaba K, Komura K, Yamazaki M, Takehara K. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 2004 63: 1514 1517. (Pubitemid 39433963)
93. Sato S, Fujimoto M, Hasegawa M, Takehara K. Antiphospholipid antibody in localised scleroderma. Ann Rheum Dis 2003 62: 771 774.
94. Black CM, Stevens WM. Scleroderma. Rheum Dis Clin North Am 1989 15: 193 212.
95. Antonioli CM, Danieli E, Airo P, Cattaneo R, Tincani A. More on anticardiolipin and anti-beta2 glycoprotein I in systemic sclerosis. Ann Rheum Dis 2003 62: 589 590.
96. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006 354: 2667 2676.
97. Loizos N, Lariccia L, Weiner J et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 2009 60: 1145 1151.
98. Svegliati S, Cancello R, Sambo P et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005 280: 36474 36482.
99. Classen JF, Henrohn D, Rorsman F et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009 60: 1137 1144.
100. Salojin KV, Le Tonqueze M, Saraux A et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997 102: 178 185.
101. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998 25: 462 466.
102. Wusirika R, Ferri C, Marin M et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 2003 120: 596 606.
103. Riccieri V, Germano V, Alessandri C et al. More severe nailfold capillaroscopy findings and anti-endothelial cell antibodies. Are they useful tools for prognostic use in systemic sclerosis? Clin Exp Rheumatol 2008 26: 992 997.
104. Ahmed SS, Tan FK, Arnett FC, Jin L, Geng YJ. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006 54: 2250 2262.